Cellectis Stock Discussion

$Cellectis(CLLS.US)$
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis announced a breakthrough in gene therapy for Sickle Cell Disease (SCD) using a non-viral approach published in Nature Communications. The therapy employs TALEN® technology for precise HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). This method achieves over 50% expression of normal hemoglobin in treated cells, effectively correcting the s...

$Cellectis(CLLS.US)$ Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
5 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE

$Cellectis(CLLS.US)$
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

$Cellectis(CLLS.US)$ The company highlighted a significant additional equity investment of $140 million from AstraZeneca, increasing their total investment to $245 million and ownership to approximately 44% of Cellectis' share capital

$Cellectis(CLLS.US)$
Cellectis Reports Financial Results for First Quarter 2024
Cellectis reported its Q1 2024 financial results revealing key business updates and financial highlights. Key points include:
Completion of a $140M equity investment by AstraZeneca, pushing the company's cash position to $143M as of March 31, 2024, and extending its cash runway projection into 2026.
Revenues for Q1 2024 were $6.5M, a significant increase from $3.6M in Q1 2023.
R&D expenses rose to $22.3...

$Cellectis(CLLS.US)$
NEWS
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.

$Cellectis(CLLS.US)$
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...

$Cellectis(CLLS.US)$
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.

$Cellectis(CLLS.US)$ Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...